Vanessa Minervini
Overview
Explore the profile of Vanessa Minervini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beltran N, Parra A, Serrano A, Castillo J, Castro I, Elsey M, et al.
J Pharmacol Exp Ther
. 2024 Jul;
391(1):30-38.
PMID: 39060162
Patients diagnosed with obesity are prescribed opioid medications at a higher rate than the general population; however, it is not known if eating a high fat diet might impact individual...
2.
Strumberger C, DEpagnier E, Nguyen K, Rogers J, Meyer M, Malhotra Y, et al.
Behav Pharmacol
. 2024 Mar;
35(2-3):122-131.
PMID: 38451024
Prescription opioids are the gold standard for treating moderate to severe pain despite their well-documented adverse effects. Of all prescription medications, opioids are abused most widely, and fatal overdoses have...
3.
Maguire D, Minervini V
Adv Pharmacol
. 2022 Mar;
93:1-33.
PMID: 35341563
Opioid abuse continues to be a significant public health challenge, with rates of opioid-related overdose deaths increasing continuously over the last two decades. There also has been a sharp increase...
4.
Minervini V, Tye C, Ghodrati S, France C
Behav Pharmacol
. 2021 Jan;
32(4):278-285.
PMID: 33491991
Intravenous drug self-administration remains the 'gold standard' for assessing abuse liability. Failure of a drug to maintain self-administration might indicate the absence of positive reinforcing effects but might also indicate...
5.
Mada S, Gerak L, Soyer A, Maguire D, Hu Z, Minervini V, et al.
Psychopharmacology (Berl)
. 2020 Aug;
237(12):3591-3602.
PMID: 32820390
Rationale: Opioids remain the drugs of choice for treating moderate to severe pain, although adverse effects often limit use. Drugs acting concomitantly as agonists at μ opioid receptors and antagonists...
6.
Minervini V, Disney A, Husbands S, France C
Psychopharmacology (Berl)
. 2020 Aug;
237(10):3057-3065.
PMID: 32772146
Rationale: Opioid abuse remains a serious public health problem. The pseudoirreversible mu opioid receptor antagonist methocinnamox (MCAM) might be useful for treating opioid abuse and overdose. Because endogenous opioid systems...
7.
Minervini V, France C
Behav Pharmacol
. 2020 Feb;
31(2&3):233-248.
PMID: 32101988
The opioid epidemic underscores the need for safer and more effective treatments for pain. Combining opioid receptor agonists with drugs that relieve pain through nonopioid mechanisms could be a useful...
8.
Maguire D, Minervini V, Dodda V, France C
Behav Pharmacol
. 2019 Oct;
31(2&3):216-220.
PMID: 31577559
The behavioral economics framework has been used extensively to study factors that control operant behavior, including quantification of reinforcing effectiveness of drugs of abuse. Generally, consumption of a commodity decreases...
9.
Gerak L, Minervini V, Latham E, Ghodrati S, Lillis K, Wooden J, et al.
J Pharmacol Exp Ther
. 2019 Aug;
371(2):507-516.
PMID: 31439807
A novel -opioid receptor antagonist, methocinnamox (MCAM), attenuates some abuse-related and toxic effects of opioids. This study further characterized the pharmacology of MCAM in separate groups of rats using procedures...
10.
Minervini V, Osteicoechea D, Casalez A, France C
Behav Pharmacol
. 2018 Oct;
30(4):335-342.
PMID: 30320606
Intravenous (i.v.) drug self-administration remains the 'gold standard' for assessing abuse potential of drugs. Failure of a drug to maintain self-administration might indicate merely the absence of positive-reinforcing effects but...